We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Celltrion Receives Complete Response Letters for Two Biosimilars
Celltrion Receives Complete Response Letters for Two Biosimilars
Celltrion received two complete response letters from the FDA regarding biologics license applications for Truxima (rituximab) and Herzuma (trastuzumab) — biosimilars of Roche`s blockbuster cancer drugs Rituxan and Herceptin.